mometasone furoate / Yarrow Bioscience - LARVOL DELTA

[VIRTUAL] Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis (RAD 2020) - P3 | " ECZTRA 3 was a double-blind, multicenter, placebo plus TCS-controlled, Phase 3 trial.1 Adult patients with atopic dermatitis for ≥1 year who were candidates for systemic therapy were randomized 2:1 to subcutaneous tralokinumab 300 mg every 2 weeks (q2w) plus TCS (mometasone furoate 0.1% cream applied once daily to active lesions as needed) or placebo plus TCS for an initial treatment period of 16 weeks. Tralokinumab plus TCS as needed provided significant improvements in the extent and severity of atopic dermatitis versus placebo plus TCS as needed at week 16 in patients with moderate-to-severe atopic dermatitis. The week 16 response rates progressively improved with continued tralokinumab plus TCS, with 70% of patients achieving EASI-75 at week 32. The extent and severity of atopic dermatitis was reduced from mean EASI and SCORAD scores equivalent to severe disease at baseline to mild at week 32."

Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13